SPC378
Anifrólúmab
Status:
VeittApplication date:
17.5.2022Application published:
15.6.2022Grant published:
15.2.2024
Max expiry date:
5.2.2034Medicine name:
SaphneloMedicine for children:
No
Timeline
Today
17.5.2022Application
15.6.2022Publication
15.2.2024Registration
5.2.2034Expires
Marketing license
IS authorization number:
EU/1/21/1623/001Date:
21.2.2022
Foreign authorization number:
EU/1/21/1623Date:
14.2.2022
Owner
Name:
AstraZeneca ABAddress:
, Södertälje SE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2250279
Deadlines
TypeDeadline until
Type: Frestur til að fara yfir drög að vottorði
Deadline until: 09.02.2024